Immatics N.V.

Immatics N.V. is a biotechnology company focused on developing innovative cancer immunotherapies by combining cancer target discovery with T cell receptor development. Their therapies, including Adoptive Cell Therapies and TCR Bispecifics, target the PRAME antigen expressed in over 50 cancers, aiming to provide new treatment options for patients worldwide.